Citi lowered the firm’s price target on Zai Lab (ZLAB) to $53 from $58 and keeps a Buy rating on the shares. The firm updated the company’s model to reflect management’s latest commentary.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Zai Lab Advances New Solid Tumor Drug ZL-1310: What Investors Should Watch
- Zai Lab’s ZL-6201 Study Advances in Sarcoma and Solid Tumors: What Investors Should Watch
- Zai Lab price target lowered to $39 from $46 at JPMorgan
- Zai Lab initiated with a Buy at UBS
- Zai Lab announces China NMPA approval for Augtryo sNDA